Herpes simplex virus-based nerve targeting gene therapy in pain management

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 71-79

  Goss, James R ^a   Krisky, David ^a   Wechuck, James ^a   Wolfe, Darren ^a  

^a PeriphaGen Inc   (United States)

Author keywords

Gene therapy; Herpes simplex virus; Inhibitory neurotransmitters; Opioids; Pain; Voltage gated sodium channels

Indexed keywords

4 AMINOBUTYRIC ACID; CYTOKINE; ENDORPHIN; ENKEPHALIN; GENE THERAPY AGENT; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; NARCOTIC ANALGESIC AGENT; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; SMALL INTERFERING RNA; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.9; VANILLOID RECEPTOR 1; VIRUS DNA; VOLTAGE GATED SODIUM CHANNEL;

CHRONIC PAIN; GENE EXPRESSION; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; NERVOUS SYSTEM FUNCTION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN RECEPTOR; REVIEW; SENSITIZATION; SYNAPSE; VIRAL GENE THERAPY; VIRUS REPLICATION;

EID: 84892888874     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S36619     Document Type: Review

References (88)

1. Institute of Medicine, editor. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press: 2001.
2. Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10): 883-891.
3. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11(11):1230-1239.
4. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;Suppl 5: 1062-1067.
5. Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823-836.
6. Boivie J, Leijon G, Johansson I. Central post-stroke pain - a study of the mechanisms through analyses of the sensory abnormalities. Pain. 1989;37(2):173-185.
7. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77-92.
8. Mizumura K. Peripheral mechanism of hyperalgesia - sensitization of nociceptors. Nagoya J Med Sci. 1997;60(3-4):69-87.
9. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications. Phys Med Rehabil Clin N Am. 2006;17(2):287-302.
10. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001;429(1-3):23-37.
11. McMahon SB, Wall PD. Receptive fields of rat lamina 1 projection cells move to incorporate a nearby region of injury. Pain. 1984;19(3): 235-247.
12. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57(1):1-164.
13. Woolf CJ. Windup and central sensitization are not equivalent. Pain. 1996;66(2-3):105-108.
14. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26(8):1235-1238.
15. Devor M. Response of nerves to injury in relation to neuropathic pain. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack's Textbook of Pain. London, UK: Elsevier; 2006.
16. Shim B, Kim DW, Kim BH, Nam TS, Leem JW, Chung JM. Mechanical and heat sensitization of cutaneous nociceptors in rats with experimental peripheral neuropathy. Neuroscience. 2005;132(1):193-201.
17. Griffin JW. The roles of growth factors in painful length-dependent axonal neuropathies. In: Campbell JN, Basbaum AI, Dray A, et al, editors. Emerging Strategies for the Treatment of Neuropathic Pain. Seattle, WA: IASP Press; 2006.
18. Boucher TJ, McMahon SB. Neurotrophic factors and neuropathic pain. Curr Opin Pharmacol. 2001;1(1):66-72.
19. Neumann S, Doubell TP, Leslie T, Woolf CJ. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature. 1996;384(6607):360-364.
20. Gold MS, Weinreich D, Kim CS, et al. Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci. 2003;23(1): 158-166.
21. Kohno T, Ji RR, Ito N, et al. Peripheral axonal injury results in reduced mu opioid receptor pre-and post-synaptic action in the spinal cord. Pain. 2005;117(1-2):77-87.
22. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-455.
23. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16(1):1-18.
24. Irving GA. Contemporary assessment and management of neuropathic pain. Neurology. 2005;64(12 Suppl 3):S21-S27.
25. Hansson P, Lacerenza M, Marchettini P. Aspects of clinical and experimental neuropathic pain: the clinical perspective. In: Hansson PT, Fields HL, Hill RG, Marchettini P, editors. Neuropathic Pain: Pathophysiology and Treatment. Seattle, WA: IASP Press; 2001.
26. Wu CL, Garry MG, Zollo RA, Yang J. Gene therapy for the management of pain. Part I: methods and strategies. Anesthesiology. 2001;94(6):1119-1132.
27. Wu CL, Garry MG, Zollo RA,Yang J. Gene therapy for the management of pain. Part II: molecular targets. Anesthesiology. 2001;95(1):216-240.
28. Eaton MJ, Plunkett JA, Martinez MA, et al. Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplant. 1999;8(1):87-101.
29. Ishii K, Isono M, Inoue R, Hori S. Attempted gene therapy for intractable pain: dexamethasone-mediated exogenous control of beta-endorphin secretion in genetically modified cells and intrathecal transplantation. Exp Neurol. 2000;166(1):90-98.
30. Duplan H, Li RY, Vue C, et al. Grafts of immortalized chromaffin cells bio-engineered to improve met-enkephalin release also reduce formalin-evoked c-fos expression in rat spinal cord. Neurosci Lett. 2004;370(1): 1-6.
31. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol. 2000;18(1):33-37.
32. Yao MZ, Gu JF, Wang JH, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience. 2002;112(2):409-416.
33. Wu CM, Lin MW, Cheng JT, et al. Regulated, electroporation-mediated delivery of pro-opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther. 2004;11(11): 933-940.
34. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40.
35. Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci. 2003;4(5):353-364.
36. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1structure, replication and pathogenesis. Neoplasia. 1999;1(5):387-401.
37. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol. 1974;14(1):8-19.
38. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985;56(2): 558-570.
39. Goins WF, Marconi P, Krisky D, et al. Construction of replication defective herpes simplex virus vectors. Curr Protoc Hum Genet. 2002;Chapter 12:Unit 12.11.
40. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther. 1997;4(10):1120-1125.
41. L flanking repeats. J Virol. 1994;68(4):2239-2252.
42. Puskovic V, Wolfe D, Goss J, et al. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther. 2004;10(1):67-75.
43. Chattopadhyay M, Wolfe D, Mata M, Huang S, Glorioso JC, Fink DJ. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther. 2005;12(2):307-313.
44. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7: 309-338.
45. Antunes Bras JM, Epstein AL, Bourgoin S, Hamon M, Cesselin F, Pohl M. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem. 1998;70(3):1299-1303.
46. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A. 1999;96(6):3211-3216.
47. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 2001;8(7):551-556.
48. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001;21(20): 7881-7888.
49. Yeomans DC, Jones T, Laurito CE, Lu Y, Wilson SP. Reversal of ongoing thermal hyperalgesia in mice by a recombinant her-pesvirus that encodes human preproenkephalin. Mol Ther. 2004;9(1): 24-29.
50. Goss JR, Harley CF, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol. 2002;52(5): 662-665.
51. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003;102(1-2):135-142.
52. Chattopadhyay M, Mata M, Fink DJ. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci. 2008;28(26):6652-6658.
53. Meunier A, Latrémolière A, Mauborgne A, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther. 2005;11(4):608-616.
54. Yokoyama H, Sasaki K, Franks ME, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther. 2009;20(1):63-71.
55. Lu Y, McNearney TA, Lin W, Wilson SP, Yeomans DC, Westlund KN. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther. 2007;15(10):1812-1819.
56. Yang H, McNearney TA, Chu R, et al. Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model. Mol Pain. 2008;4:8.
57. Yeomans DC, Lu Y, Laurito CE, et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther. 2006;13(3):589-597.
58. Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70(2):207-212.
59. Zhou HY, Zhang HM, Chen SR, Pan HL. Increased nociceptive input rapidly modulates spinal GABAergic transmission through endog-enously released glutamate. J Neurophysiol. 2007;97(1):871-882.
60. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol. 2005;57(6):914-918.
61. Miyazato M, Sugaya K, Saito S, et al. Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. J Urol. 2010;184(3):1204-1210.
62. Liu J, Wolfe D, Hao S, et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther. 2004;10(1):57-66.
63. Chattopadhyay M, Mata M, Fink DJ. Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur J Pain. 2011;15(9):913-920.
64. Wolfe D, Hao S, Hu J, et al. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain. 2007;133(1-3):29-38.
65. Hao S, Wolfe D, Glorioso JC, Mata M, Fink DJ. Effects of t{stroke}ransgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain. 2009;13(4):380-386.
66. Cunha FQ, Poole S, Lorenzetti BB, Veiga FH, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol. 1999;126(1):45-50.
67. Lorenzetti BB, Poole S, Veiga FH, Cunha FQ, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. Eur Cytokine Netw. 2001;12(2):260-267.
68. Poole S, Cunha FQ, Selkirk S, Lorenzetti BB, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol. 1995;115(4):684-688.
69. Vale ML, Marques JB, Moreira CA, et al. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther. 2003;304(1):102-108.
70. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain. 1998;74(1): 35-42.
71. Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain. 2006;2:6.
72. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007;14(13): 1010-1016.
73. Zhou Z, Peng X, Hao S, Fink DJ, Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther. 2008;15(3):183-190.
74. Milligan ED, Langer SJ, Sloane EM, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci. 2005;21(8):2136-2148.
75. Milligan ED, Sloane EM, Langer SJ, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
76. Goss JR, Gold MS, Glorioso JC. HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain. Gene Ther. 2009;16(4):493-501.
77. Srinivasan R, Wolfe D, Goss J, et al. Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsalroot ganglion neurons. Eur J Neurosci. 2008;28(7):1241-1254.
78. Goss JR, Cascio M, Goins WF, et al. HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation. Mol Ther. 2011;19(3):500-506.
79. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131(3): 243-257.
80. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121): 894-898.
81. Waxman SG. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat Neurosci. 2007;10(4):405-409.
82. Chattopadhyay M, Zhou Z, Hao S, Mata M, Fink DJ. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol Pain. 2012;8:17.
83. Yeomans DC, Levinson SR, Peters MC, et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther. 2005;16(2): 271-277.
84. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257-262
85. Goss JR, Fetterfolf C, Gains W, et al. Engineered zinc finger protein transcription factors as a potential therapy for neuropathic pain. Presented at the 12th World Congress on Pain, Glasgow, Scotland, August 17-22, 2008.
86. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005;12(2):189-211.
87. Wu Z, Mata M, Fink DJ. Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element. Gene Ther. 2012;19(11):1107-1113.
88. Zou W, Huang C, Yang Y, Pan Y, Yan J, Guo Q. Microinjection of HSV-1 amplicon vector-mediated human proenkephalin into the periaqueductal grey attenuates neuropathic pain in rats. Int J Neurosci. 2012;122(4):189-194.